title: Stents Coated With Mammalian Target of Rapamycin Inhibitors (mTOR) Appear to Be the Best Choice in Patients With Antiphospholipid Syndrome and Myocardial Infarction.
authors.affiliation: Department of Immunology Instituto Nacional de Cardiología Ignacio Chávez, Mexico City Mexico Coronary Care Unit Instituto Nacional de Cardiología Ignacio Chávez, Mexico City Mexico Department of Immunology Instituto Nacional de Cardiología Ignacio Chávez; and Health Care Department Universidad Autónoma Metropolitana-Xochimilco, Mexico City Mexico lmamezcuag@gmail.com.
authors.forename: Mauricio
authors.initials: M
authors.lastname: Mora-Ramírez
authors.forename: Hector
authors.initials: H
authors.lastname: González-Pacheco
authors.forename: Luis M
authors.initials: LM
authors.lastname: Amezcua-Guerra
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation* / Q000379:methods; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology; D017023:Coronary Angiography / Q000379:methods; D023903:Coronary Restenosis / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery; D003331:Coronary Vessels / Q000000981:diagnostic imaging; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000209:etiology / Q000601:surgery; D012086:Reoperation / Q000295:instrumentation* / Q000379:methods; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus